Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Jeffrey S. Heier Sells 2,948 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey S. Heier sold 2,948 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the transaction, the insider now directly owns 269,059 shares in the company, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ocular Therapeutix Stock Up 3.2 %

Shares of NASDAQ:OCUL opened at $10.06 on Friday. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average is $9.96 and its 200 day moving average is $8.22. Ocular Therapeutix, Inc. has a 1 year low of $2.16 and a 1 year high of $11.77.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Robert W. Baird reduced their price target on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. HC Wainwright raised their price objective on Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Scotiabank initiated coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Deltec Asset Management LLC boosted its position in Ocular Therapeutix by 9.6% in the second quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock valued at $17,717,000 after buying an additional 226,181 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Ocular Therapeutix by 1,142.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock worth $6,031,000 after acquiring an additional 609,328 shares during the period. Vanguard Group Inc. raised its holdings in shares of Ocular Therapeutix by 41.4% during the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock worth $65,840,000 after purchasing an additional 2,117,029 shares during the last quarter. Cetera Advisors LLC lifted its position in Ocular Therapeutix by 1,455.0% during the first quarter. Cetera Advisors LLC now owns 723,490 shares of the biopharmaceutical company’s stock valued at $6,584,000 after purchasing an additional 676,963 shares during the period. Finally, Banco Santander S.A. boosted its holdings in Ocular Therapeutix by 81.3% in the second quarter. Banco Santander S.A. now owns 377,368 shares of the biopharmaceutical company’s stock valued at $2,581,000 after purchasing an additional 169,172 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.